Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer

Cancer Lett. 2005 Apr 28;221(2):185-90. doi: 10.1016/j.canlet.2004.11.012.

Abstract

In a population-based case-cohort study, we have investigated the occurrence of lung cancer in relation to polymorphisms in the phase I gene cytochrome P450 1B1 and in the phase II genes glutathione S-transferase A1, NAD(P)H quinone oxidoreductase and N-acetyltransferase 2 (NAT2). Among 54,220 cohort members, 265 lung cancer cases were identified and a sub-cohort comprising 272 individuals was used for comparison. No overall associations were found between the polymorphisms and risk of lung cancer. The NAT2 fast acetylator genotype seemed to be protective against lung cancer in light smokers (< or =20 cigarettes/day) and not among heavy smokers (>20 cigarettes/day).

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aryl Hydrocarbon Hydroxylases
  • Arylamine N-Acetyltransferase / genetics*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Carcinoma, Small Cell / genetics
  • Carcinoma, Squamous Cell / genetics
  • Carrier Proteins / genetics*
  • Case-Control Studies
  • Cohort Studies
  • Cytochrome P-450 CYP1B1
  • Cytochrome P-450 Enzyme System / genetics*
  • Glutathione Transferase
  • Humans
  • Lung Neoplasms / genetics*
  • Middle Aged
  • NAD(P)H Dehydrogenase (Quinone) / genetics*
  • Polymorphism, Genetic*
  • Prospective Studies
  • Risk Factors
  • Smoking / adverse effects
  • Smoking / genetics*

Substances

  • Carrier Proteins
  • Cytochrome P-450 Enzyme System
  • Aryl Hydrocarbon Hydroxylases
  • CYP1B1 protein, human
  • Cytochrome P-450 CYP1B1
  • NAD(P)H Dehydrogenase (Quinone)
  • NQO1 protein, human
  • Arylamine N-Acetyltransferase
  • NAT2 protein, human
  • GSTA1 protein, human
  • Glutathione Transferase